Glaxo and Vir COVID-19 Treatment Meets Endpoint in Phase III Study – Community News
Covid-19

Glaxo and Vir COVID-19 Treatment Meets Endpoint in Phase III Study

A Phase III study of intramuscular administration of sotrovimab met the primary endpoint of non-inferiority to intravenous administration for early treatment of COVID-19 in high-risk adults and adolescents, GlaxoSmithKline GSK,
+0.12%
GSK,
+0.30%
and Vir Biotechnology VIR,
+2.54%
said. The companies noted that the trial was conducted during the height of the Delta variant in Florida. “We designed sotrovimab to be resistant to the variants we expected to occur, and these data show that sotrovimab administered by IV or IM may prove important in the fight against COVID-19 after authorization,” said Vir CEO George Scangos. UK-listed Glaxo shares were up 0.3%, while Vir shares were up 4% in premarket trading.